- Home
- NODK vs ITOS Comparison
NODK vs ITOS Comparison
Compare NODK & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- ITOS
- Stock Information
- Founded
- NODK 1946
- ITOS 2011
- Country
- NODK United States
- ITOS United States
- Employees
- NODK N/A
- ITOS N/A
- Industry
- NODK Property-Casualty Insurers
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NODK Finance
- ITOS Health Care
- Exchange
- NODK Nasdaq
- ITOS Nasdaq
- Market Cap
- NODK 309.9M
- ITOS 272.5M
- IPO Year
- NODK 2017
- ITOS 2020
- Fundamental
- Price
- NODK $14.97
- ITOS $7.59
- Analyst Decision
- NODK
- ITOS Strong Buy
- Analyst Count
- NODK 0
- ITOS 3
- Target Price
- NODK N/A
- ITOS $21.33
- AVG Volume (30 Days)
- NODK 10.7K
- ITOS 268.0K
- Earning Date
- NODK 03-14-2025
- ITOS 03-05-2025
- Dividend Yield
- NODK N/A
- ITOS N/A
- EPS Growth
- NODK N/A
- ITOS N/A
- EPS
- NODK N/A
- ITOS N/A
- Revenue
- NODK $391,655,000.00
- ITOS $35,000,000.00
- Revenue This Year
- NODK N/A
- ITOS $271.18
- Revenue Next Year
- NODK N/A
- ITOS N/A
- P/E Ratio
- NODK N/A
- ITOS N/A
- Revenue Growth
- NODK 22.91
- ITOS N/A
- 52 Week Low
- NODK $13.16
- ITOS $7.09
- 52 Week High
- NODK $17.24
- ITOS $18.75
- Technical
- Relative Strength Index (RSI)
- NODK 46.09
- ITOS 43.24
- Support Level
- NODK $14.34
- ITOS $7.30
- Resistance Level
- NODK $15.41
- ITOS $7.91
- Average True Range (ATR)
- NODK 0.26
- ITOS 0.32
- MACD
- NODK 0.08
- ITOS -0.02
- Stochastic Oscillator
- NODK 58.88
- ITOS 17.82
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.